Literature DB >> 7195487

Dystrophic axons and spinal cord demyelination in cystic fibrosis.

S J Cavalier, P Gambetti.   

Abstract

Neuropathologic changes in patients with cystic fibrosis include dystrophic axons in the nucleus gracilis and demyelination of the fasciculus gracilis. We reviewed 43 autopsy cases of cystic fibrosis to determine the incidence and severity of these changes. Sixty-six percent of patients developed dystrophic axons. There was a direct correlation between severity of neuroaxonal dystrophy and duration of disease. Demyelination of the fasciculus gracilis occurred in 11%. The neuropathology of cystic fibrosis resembles that of vitamin E deficiency in animals. However, vitamin E replacement failed to prevent neuropathologic changes in these patients.

Entities:  

Mesh:

Year:  1981        PMID: 7195487     DOI: 10.1212/wnl.31.6.714

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  4 in total

1.  Amyloid precursor protein and ubiquitin immunoreactivity in dystrophic axons is not unique to Alzheimer's disease.

Authors:  E Cochran; B Bacci; Y Chen; A Patton; P Gambetti; L Autilio-Gambetti
Journal:  Am J Pathol       Date:  1991-09       Impact factor: 4.307

2.  Evidence of subclinical extrapyramidal hemosiderosis in cystic fibrosis.

Authors:  T Wongmongkolrit; R Wyszynski; C O Hershey; A W Varnes
Journal:  Acta Neuropathol       Date:  1985       Impact factor: 17.088

3.  A study of the relationship between neurological function and serum vitamin E concentrations in patients with cystic fibrosis.

Authors:  H J Willison; D P Muller; S Matthews; S Jones; A Kriss; R J Stead; M E Hodson; A E Harding
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-11       Impact factor: 10.154

4.  Expression and distribution of cystic fibrosis transmembrane conductance regulator in neurons of the spinal cord.

Authors:  Yong Guo; Min Su; Meng Su; Michael A McNutt; Jiang Gu
Journal:  J Neurosci Res       Date:  2009-12       Impact factor: 4.164

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.